Remediate, Reprice, Reduce, or Exit: A Governance Test

Turning a Diagnosis Into a Decision

Identifying that a network average hides real provider price variation is not the same as deciding what to do about it. Too often, that identification sits in an analyst's report without triggering a defined response, and the underpriced exposure simply continues into the next renewal cycle unchanged. A structured test, applied consistently by the board or risk committee, closes that gap by forcing a decision among a fixed set of options.

What Is the Remediate, Reprice, Reduce, or Exit Test?

It is a board-level decision framework applied to any treaty or provider exposure where hidden price variation has been identified. Rather than allowing an open-ended monitoring period, the test forces a clear choice among four defined responses within a set timeframe, ensuring that a known risk does not simply persist by default. Each of the four options carries a different cost and a different risk profile, and the discipline of the test is requiring an explicit choice among them rather than letting the decision drift.

Why Do Boards Need a Structured Test Instead of Case-by-Case Decisions?

Because ad hoc responses to underpriced provider exposure tend to default to inaction. Without a defined framework, a flagged provider risk often gets acknowledged, discussed, and then carried forward to the next review cycle without a firm decision, since no single option is forced onto the table. A structured test removes that default by requiring the board to explicitly select and document one of the four responses, with a named owner and a timeline for execution.

What Does Remediate Mean in This Framework?

It means correcting the pricing or contract terms on the specific exposure identified, without changing the overall network relationship. Typically this involves renegotiating discount terms with the highest-risk providers, or moving those specific providers from a percent-of-billed arrangement to a fixed fee schedule. Research from Serif Health found percent-of-billed contracts were costlier than fixed fee schedules in over half of cases reviewed, with the gap exceeding 70 percent of cases at some health systems, which makes remediation through contract structure a concrete, achievable response rather than a vague aspiration.

When Is Reprice the Right Response Instead of Remediation?

When the underlying provider relationship is fundamentally sound, but the treaty premium simply has not kept pace with the actual cost the network is generating. In this case, renegotiating individual provider contracts is unnecessary, the fix is adjusting the treaty terms at the next renewal to reflect the provider-level pricing data now available. This is the natural governance follow-through to the capital allocation questions raised in what network averages hide about health provider capital risk, where the underpricing was identified but not yet corrected.

What Triggers a Reduce Decision?

A pattern where a specific provider or network segment consistently generates disproportionate cost relative to its claims volume, even after remediation attempts. In that situation, reducing exposure through narrower network design becomes more defensible than continued remediation, since the data shows the relationship itself, not just its contract terms, is the source of the risk. Reduce decisions require the same provider-level utilization data described in building a decision-ready view of health provider inflation risk, since a board cannot responsibly narrow a network without knowing which specific providers to remove.

When Should a Board Consider Exit as the Response?

When a treaty's provider risk profile cannot be remediated, repriced, or reduced within an acceptable timeframe, and continued unpriced exposure would materially affect the balance sheet. Exit is the most disruptive of the four options, and boards should reserve it for cases where the other three have genuinely been assessed and ruled out, not used as a default response to avoid the harder work of remediation or repricing. Claims leakage adds urgency to this assessment when present, since undetected leakage compounds legitimate provider price variation into a larger combined problem, a dynamic covered in claims leakage in high-volume health portfolios.

How Does This Test Fit Into Existing Governance Calendars?

It should run alongside treaty renewal reviews, using the same provider-level pricing data that underwriting and actuarial teams maintain as part of their standing analytics process. That alignment avoids creating a separate, competing governance exercise, and ensures the board is applying the test to current data rather than a stale annual snapshot. Network Adequacy Analysis AI Agent can support this by keeping provider-level pricing and utilization data current between renewal cycles, so the board's test is always applied to a recent picture rather than a lagging one.

What Evidence Should Support Each of the Four Decisions?

Provider-level percentile pricing data, claims mix by provider, and a documented cost-benefit comparison across all four options, so the board's decision is defensible to regulators and rating agencies. That documentation matters as much as the decision itself, since a board that can show it systematically considered all four responses, with supporting data, has a materially stronger governance record than one that simply notes a risk was "monitored." Treaty economics pressure from broader medical trend, covered in medical trend outpacing treaty economics, makes this documentation more important still, since boards will increasingly need to show they distinguished provider-specific risk from general market trend when explaining pricing decisions.

What Does a Successful Remediation Look Like in Practice?

Concretely, it looks like a defined provider segment moving from a percent-of-billed arrangement to a fixed fee schedule within a set number of renewal cycles, with the resulting cost reduction tracked and reported back to the board as evidence the remediation choice worked. A board that selects remediate without setting a measurable target and a follow-up checkpoint has effectively made a monitoring decision dressed up as a remediation decision, which is exactly the drift the four-option test is designed to prevent.

How Should Success Be Measured?

Against the provider-level percentile pricing data used to identify the original problem, not against a general improvement in the network's headline discount rate. If a remediated provider segment's actual dollar cost, benchmarked against the same percentile data, has moved meaningfully closer to the network median, the remediation has worked. If the headline discount rate improved while dollar costs stayed flat or grew, the board is looking at the exact obscuring effect this whole framework exists to catch, and the case should be escalated to reprice or reduce instead.

How Does This Test Apply to Multi-Year Treaties?

With a built-in review checkpoint, since a multi-year treaty term should not mean a multi-year gap in applying this test. Boards should require that any multi-year health treaty include an annual provider price review clause, so the remediate, reprice, reduce, or exit decision can be revisited before the full multi-year term elapses, rather than discovering at the end of a three-year treaty that provider price drift went unaddressed for its entire duration. Without that clause, a multi-year treaty effectively locks in whatever pricing gap exists at inception, insulated from the very oversight process this framework is meant to provide.

What Should Trigger an Interim Review Within a Multi-Year Term?

A material shift in claims mix toward higher-cost providers, a significant update to hospital price transparency data showing the network's percentile position has moved, or claims experience deteriorating meaningfully faster than the medical trend assumption built into the treaty. Any one of these should be enough to bring the four-option test back to the board before the treaty's scheduled renewal, rather than waiting out a multi-year term on the assumption that the original pricing remains adequate throughout.

Should This Test Results Be Shared With Rating Agencies?

Selectively, and generally to the organization's advantage. A board that can demonstrate a systematic, documented process for identifying and responding to provider price risk is showing exactly the kind of disciplined risk management rating agencies look for, and sharing a summary of how the test has been applied can support a stronger overall risk management assessment rather than exposing a weakness. The key is framing it correctly, presenting the test as an active governance capability that catches and resolves pricing risk, not as an admission that provider price problems exist in the portfolio. Boards that get this framing right tend to find rating agencies respond favorably to the underlying discipline, even when a specific remediation is still in progress.

A structured test does not make every decision easy, remediation and network redesign both take real operational effort to execute well. What it does is ensure a known, quantified risk never simply carries forward unaddressed for lack of a forcing mechanism, which is the governance failure that turns a hidden pricing problem into a realized loss.

Sources

• RAND Hospital Price Transparency Study, Round 5.0 (via The Alliance)
• Serif Health: Why Discounts Aren't Enough